Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Blood cancer market will not be able to sustain oversaturated cell therapy pipeline should they receive regulatory approval, says GlobalData

Cell therapies are among the most researched treatment types for blood cancer and the product pipeline is oversaturated, with GlobalData revealing that there are over 800 products currently in development for just five major blood cancers*. The leading data and analytics company warns that the blood cancer market will not be able to sustain this […]
Read more

AI and blockchain best poised to support optimization of electronic health records, according to GlobalData polls

Artificial Intelligence (AI) and blockchain stand out as the technologies poised to best support the optimization of electronic health records (EHRs), according to GlobalData, a leading data and analytics company. A recent poll published in GlobalData’s report, ‘Electronic Health Records – Physician Perspective Report’, revealed that AI (30%) was noted as the innovation that is best positioned […]
Read more

Ashvattha’s new self-administered anti-VEGF therapy has potential to address unmet needs for diabetic macular edema, says GlobalData

Ashvattha Therapeutics has recently presented the safety data from a Phase 1 study of its lead diabetic macular edema (DME) candidate D-4517.2 at the Association for Research in Ophthalmology (ARVO). Against this backdrop, the drug has potential to address a key unmet need for drugs that reduce patient burden and compliance-related issues, says GlobalData, a […]
Read more

Implementation of electronic health records could lead to improved quality of care, says GlobalData

The adoption of electronic health records (EHR) is set to bring a number of benefits for patients, healthcare professionals, and healthcare systems, as they have the potential to improve patient care by enabling timelier, safer, and more cost-effective decision-making, says GlobalData a leading data and analytics company. Urte Jakimaviciute, Senior Director of Market Research at […]
Read more

New treatment options in development for schizophrenia could provide more complete symptom relief to larger patient population, says GlobalData

It is an exciting time within the schizophrenia market as numerous monotherapies and adjunctive therapies are being developed to address some of the most important unmet needs observed with current antipsychotic treatments, says GlobalData. Key opinion leaders (KOLs) interviewed by the leading data and analytics company were hopeful that these novel pipeline agents might help […]
Read more

Alzheimer’s disease space suffered setbacks in June but drug companies remain hopeful, says GlobalData

With rapidly increasing worldwide prevalence, Alzheimer’s disease (AD) has been identified as a major global health threat by the international medical community. However, June was fairly disappointing for the AD space with several companies announcing negative results from clinical trials and other news for pipeline products, found GlobalData. Despite these setbacks, the leading data and […]
Read more

Venture financing deal value for US-headquartered biotechs decreased by 46% in Q1 2022 compared to Q1 2021, finds GlobalData

Venture financing deal value for US-headquartered biotech companies decreased by 46% in Q1 2022 compared to Q1 2021, according to GlobalData. The leading data and analytics company notes that this decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, MPH, Business […]
Read more

Gut microbiome offers huge, unlocked potential for treating infectious diseases—including COVID-19, says GlobalData

Gut health is linked to diseases ranging from cancer, diabetes, and depression 43% of microbiome-targeting therapies for infectious diseases are being investigated in Clostridioides difficile infections (CDIs) Data show that viral shedding of COVID-19 in stool samples persist much longer than in respiratory samples, potentially playing a role in long COVID Rebiotix is the strongest player, and will […]
Read more

FDA rejects approval of novel oral antibiotic tebipenem Hbr, further increasing the threat of antibiotic resistance, says GlobalData

Following the news that the Food and Drug Administration (FDA) has denied marketing approval for Spero Therapeutics’ tebipenem Hbr; Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “There is a high unmet need for new oral antibiotics which are effective against multidrug-resistant bacterial strains. Filling this gap […]
Read more

Bronchiectasis treatment market set to provide more options for patients with 14 agents in development, says GlobalData

Due to the heterogeneity of bronchiectasis as well as the complex pathophysiology of the disease, the current bronchiectasis market suffers from a lack of disease modifying therapies, says GlobalData. The leading data and analytics company notes that 14 drugs are currently under development in the bronchiectasis pipeline focussing on a variety of disease modifying mechanisms […]
Read more

The significant unmet needs in OA treatment gives pharma companies the opportunity to create novel DMOADs, says GlobalData

There is a high level of unmet medical needs in the Osteoarthritis (OA) market such as the lack of disease-modifying OA drugs (DMOADs) and the need for effective analgesics with fewer adverse effects. This provides pharmaceutical companies with the opportunity to develop new drugs with disease-modifying effects and novel methods of action (MOAs) that are […]
Read more

Sanofi and Regeneron’s additional label expansion for Dupixent reinforces its dominance in the atopic dermatitis market, says GlobalData

The Food and Drug Administration’s (FDA) approval for Sanofi and Regeneron’s interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), for the treatment of children ages 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) earlier this month, has solidified first-mover advantage for Dupixent and reinforces its market-leading position for the treatment of moderate-to-severe AD, says GlobalData, a […]
Read more

India’s first domestically produced HPV vaccine by SII to improve affordability for those most at need, says GlobalData

Serum Institute of India’s (SII) Cervavac—a quadrivalent human papillomavirus (qHPV) vaccine— is likely to be the first indigenous qHPV vaccine to be approved in India, according to GlobalData. The leading data and analytics company notes that this will not only make the drug more affordable to Indians, but it will significantly improve the overall penetration […]
Read more
1 … 46 47 48 49 50 … 110